Another multinational pharmaceutical company splits up mature products

Recently, Daiichi Sankyo announced at a board meeting that it had passed a resolution to transfer the production and sales rights of the company’s 11 mature drugs in Japan to Alfresa’s subsidiary, Alfresa Pharmaceuticals.

Daiichi Sankyo stated that it is currently accelerating the transformation of new pharmaceutical business, increasing investment to maximize the value of the drug pipeline in the oncology field, and realizing the vision of becoming a "global drug innovator with competitive advantages in the oncology field" by 2025.

Alfresa Pharmaceuticals is a large-scale comprehensive pharmaceutical distribution company in Japan.

In the last fiscal year ending March 31, 2020, the sales revenue of these 11 products of Daiichi Sankyo was approximately 4.

Due to the company's spin-off, Daiichi Sankyo expects that in fiscal 2021, net assets will decrease by nearly 10% and net sales will decrease by 3% compared to the previous year.

Alfresa Pharma also announced this news yesterday.

Friends who pay attention to the daily sharing of Dami should know that in the past two years, many multinational pharmaceutical companies have split mature products and focus on high-value disease fields, such as Pfizer spin-off Pultron, Merck spin-off Ogalon, etc.